Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Morpholines (i.e., fully hydrogenated 1,4- oxazines)

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514183000 - Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI

514228800 - Hetero ring is six-membered and includes at least nitrogen and oxygen as ring hetero atoms (e.g., monocyclic 1,2- and 1,3-oxazines, etc.)

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514231500 Additional hetero ring attached directly or indirectly to the morpholine ring by nonionic bonding 2632
514237800 Nitrogen attached indirectly to the morpholine ring by acyclic nonionic bonding 82
514238800 Chalcogen attached indirectly to the morpholine ring by acyclic nonionic bonding 61
514237500 Having -C(=X)-, wherein X is chalcogen, bonded directly to the morpholine ring 54
514239500 Carbocyclic ring attached indirectly to the morpholine ring by nonionic bonding 38
Entries
DocumentTitleDate
20100041648METHODS FOR TREATING RETROVIRAL INFECTIONS - The present invention provides compositions for treating an HIV infection comprising administering a compound according to formula I where Ar, R02-18-2010
20100105672Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same - Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.04-29-2010
20100105671C7-fluoro substituted tetracycline compounds - The present invention is directed to a compound represented by Structural Formula (A):04-29-2010
20090270384MORPHOLINE DOPAMINE AGONISTS - The present invention provides for compounds of formula (I), (Ia) and (Ib)10-29-2009
20090012074Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the Dopamine D3 receptor - The present invention relates to aromatic compounds of the formula I01-08-2009
20120322796BENZOCYCLOHEPTANE AND BENZOXEPINE DERIVATIVES - The present invention relates to a compound of formula (I)12-20-2012
20100249125INHIBITION OF PROSTGLANDIN E2 RECEPTORS FOR THE TREATMENT OF ENDOMETRIOSIS - The present invention describes the selective inhibition of prostaglandin receptors (PGE09-30-2010
20090312315PAI-1 INHIBITOR - The compound represented by the following formula (I) and the like have PAI-1 inhibition activity;12-17-2009
20100113438CLASS OF HISTONE DEACETYLASE INHIBITORS - New histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH05-06-2010
20090062271Antithrombotic Diamides - This application relates to a compound of formula I (or a pharmaceutically acceptable salt of the compound) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.03-05-2009
20090286776HEXENOIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC APPLICATIONS THEREOF - Compounds of the formula (I): in which R, R11-19-2009
20090118268OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS - This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.05-07-2009
20090286775Bicyclic Derivatives as P38 Kinase Inhibitors - New bicyclic derivatives of formula (I), wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as p38 kinase inhibitors.11-19-2009
20090170842BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE - A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically acceptable salt thereof, or analog thereof, and a pharmaceutically acceptable carrier containing the compound. The pharmaceutically acceptable carrier can be configured for oral, systemic, transdermal, intranasal, suppository, parenteral, intramuscular, intravenous, or subcutaneous administration. The compound can be present in the composition in a therapeutically effective amount for treating, inhibiting, and/or preventing breast and/or ovarian cancer. Also, the compound can be present in a therapeutically effective amount for enhancing production of BRCA1.07-02-2009
20080261966BIS-ARYL SULFONAMIDES - Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.10-23-2008
20090156591Thiophene and Thiazole Substituted trifluoroethanone Derivatives as Histone Deacetylase (Hdac) Inhibitors - The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt or stereoisomer thereof. The compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases.06-18-2009
20090054426TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS - A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.02-26-2009
20090105238Compounds and Relative use for the Control of Phytopathogens - Amphoteric compounds are described, having a zwitterionic structure of the betainic type having general formula (I)04-23-2009
20090048243THERAPEUTIC AGENT FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER - A prophylactic and/or therapeutic drug for AD/HD, containing teniloxazine or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, as the active ingredient.02-19-2009
20100152179TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS - A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.06-17-2010
20090075994DEUTERIUM-ENRICHED RADAFAXINE - The present application describes deuterium-enriched radafaxine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-19-2009
20090075993Pharmaceutically effective compounds - The subject invention relates to carboxamidine derivatives, to pharmaceutical compositions comprising the same, and the use thereof in the preparation of pharmaceutical compositions for the treatment of vascular diseases.03-19-2009
20100222337FUNGICIDAL COMPOSITION CONTAINING CARBOXYLIC ACID AMIDE DERIVATIVE - Conventional fungicidal compositions have had practical problems such that either a preventive effect or a curative effect is inadequate, the residual effect tends to be inadequate, or the controlling effect against plant diseases tends to be inadequate depending upon the application site, and a fungicidal composition to overcome such problems has been desired. The present invention provides a fungicidal composition containing a carboxylic acid amide derivative of the formula (I) or a salt thereof, as an active ingredient: wherein A is phenyl which may be substituted, benzodioxolanyl which may be substituted, or benzodioxanyl which may be substituted; B is 2- or 3-pyridyl which may be substituted; each of R09-02-2010
20090318433VERY FAST TIME RESOLVED IMAGING IN MULTIPARAMETER MEASUREMENT SPACE - The present invention provides new method of treatment of Parkinson's disease, obstructive sleep apnea, narcolepsy, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamine derivatives that constitute antagonists of the H12-24-2009
20110118254THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE - The main object of the present invention is to provide an agent for the treatment of inflammatory bowel diseases.05-19-2011
20090215764Antimicrobial agents - Provided herein are substituted aromatic compounds, which are tRNA synthetase inhibitors, and hence can be used as antimicrobial agents. Compounds described herein can be used for the treatment or prevention of a condition caused by or contributed to by gram positive, gram negative, anaerobic bacteria or fungal organisms, more particularly against bacterium, for example, 08-27-2009
20090118267INDANES - Compounds of the formula (I), in which R05-07-2009
20100286138Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide - Polymorphic forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide are provided together with a process for the manufacture of said compound.11-11-2010
20120309753METHOD OF DISSOLVING ANTIFUNGAL AGENT, AND COMPOSITIONS WITH A HIGH CONCENTRATION OF ANTIFUNGAL AGENT, SUITABLE FOR APPLICATION TO THE NAIL - A pharmaceutical composition is described which includes: an antifungal agent from the class of the allylamines or the morpholines, at a concentration of at least 5%; a ternary solvent system comprising water; at least one branched or straight chain C2-C8 alkanol; at least one glycol; the total amount of water representing more than 30% (w/w) of the composition. This composition is intended for application to the nail for the treatment of onychomycoses.12-06-2012
20110190285METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT - The present invention provides methods of treating a botulinum toxin related condition in a subject. In certain embodiments, the methods involve administering a compound of the following formulas: (I), (II), (III), (IV), (V).08-04-2011
20100022526PYRIDAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES - The present invention relates to compounds of formula (I) wherein R01-28-2010
20090170841Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders - The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.07-02-2009
20100184757FUNGICIDALLY ACTIVE COMPOUND COMBINATIONS - Active compound mixtures comprising ipconazole and at least one further fungicidally active compound are highly suitable for protecting industrial materials against colonization and destruction by microorganisms.07-22-2010
20090105237Cooling compounds - A method of conferring a cooling effect on the skin or mucous membranes by applying thereto at least one compound of the Formula I:04-23-2009
20120165325Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide - Polymorphic forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide are provided together with a process for the manufacture of said compound.06-28-2012
20100048550SELECTIVE TR-BETA 1 AGONIST - The present invention relates to novel compounds of general formula (I) which are thyroid receptor ligands and are preferably selective for the thyroid hormone receptor beta(TR-Beta). Further, the present invention relates to processes of preparing such compounds, their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, methods for using such compounds and pharmaceutical compositions containing them.02-25-2010
20100035873Diaryl Compounds and Uses Thereof - The invention relates to derivatives of a compound of formula I:02-11-2010
20110046128NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS - A series of novel compounds showing anticonvulsant, chemical countermeasure(s), and analgesic activities is described. Such pharmaceutically active compounds may also show utility in the treatment of other central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, Parkinson's disease, spasticity, Alzheimer's disease, and bipolar disorder. Furthermore, such compounds may additionally find utility as analgesics (e.g., for the treatment of chronic or neuropathic pain) and as neuroprotective agents useful in the treatment of stroke(s), chronic neurodegenerative diseases (such as Alzheimer's disease and Huntington's disease), and/or traumatic brain and/or spinal cord injuries. Moreover, these/such compounds may also be useful in the treatment of status epilepticus and/or as chemical countermeasures.02-24-2011
20100063044SUBSTITUTED ANILINE DERIVATIVES - The present invention relates to aniline derivatives of formula I:03-11-2010
20100048549Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 - The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein A, D, E, J, Q1 R1, R2, R3, p and j are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes sst02-25-2010
20100173904Topical composition, topical composition precursor, and methods for manufacturing and using - A tropical composition is provided. The topical composition can be prepared by diluting a topical composition precursor with water and adding additional components, if desired. The topical composition precursor can be prepared by melt processing a hydrophobic polymer composition that includes repeating pyrrolidone/alkylene groups wherein the alkylene groups contain at least 10 carbon atoms, and a hydrophilic polymer composition including repeating carboxylic groups and/or repeating hydroxyl groups. A topical composition precursor and methods for manufacturing and using a topical composition are provided by the invention.07-08-2010
20110160200Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension - The invention relates to methods of treating, preventing or delaying the onset or development of pulmonary hypertension using hydroxyl donors or pharmaceutically acceptable salts thereof. The invention further relates to methods of reducing mean pulmonary arterial pressure using hydroxyl donors or pharmaceutically acceptable salts thereof.06-30-2011
20080249088Topical Delivery of Antifungal Drugs - A topical formula for treatment of antifungal infections of the skin and nails comprises: (a) a therapeutically effective amount of a benzylamine or morpholine antifungal compound; (b) an aliphatic alcohol substituted with an aromatic substituent in which the antifungal compound is soluble to a degree that a therapeutically effective concentration of the antifungal compound can be applied topically in solution; and (c) a distribution solvent or mixture of solvents in which the solvent mixture of parts (a) and (b) is soluble, and which has a boiling point that is less than about 110.degree.C. The benzylamine compound can be butenafine. The morpholine compound can be amorolfine. The aliphatic alcohol substituted with an aromatic substituent can be benzyl alcohol, or phenethyl alcohol. The distribution solvent mixture can include ethyl alcohol, water, or isopropyl alcohol. Alternatively, the formula can include a second antifungal compound.10-09-2008
20130150357HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE - The invention provides hydroxybupropion analogues capable of inhibiting the reuptake of one or more monoamines and/or acting as antagonists at nicotinic acetylcholine receptors. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin and/or may selectively bind to one or more nicotinic acetylcholine receptor subtypes. Such compounds may be used to treat conditions that are responsive to modification of monoamine levels and/or antagonism of nicotinic acetylcholine receptors, including drug dependency, depression, and obesity.06-13-2013
20130203752PHENYLMORPHOLINES AND ANALOGUES THEREOF - Provided herein are compounds and prodrugs and methods of preparation of compounds and prodrugs that are capable of functioning as releasers and/or uptake inhibitors of one or more monoamine neurotransmitters, including dopamine, serotonin, and norepinephrine. Also provided are pharmaceutical compositions comprising one or more of these compounds or prodrugs, which may further comprise one or more additional therapeutic agents. Also provided are methods of treatment of various conditions that may be responsive to modification of monoamine neutrotransmitter levels, such as pre-obesity, obesity, addiction, and depression.08-08-2013

Patent applications in class Morpholines (i.e., fully hydrogenated 1,4- oxazines)

Patent applications in all subclasses Morpholines (i.e., fully hydrogenated 1,4- oxazines)